Article Sidebar

pdf
Date Published: 09/04/2025
Abstract Views: 75
Views pdf: 33
DOI: https://doi.org/10.51298/vmj.v548i1.13363
Issue
Vol. 548 No. 1 (2025)
Section
Các bài báo
How to Cite
Cấn Xuân, H., & Đinh Văn, L. (2025). EVALUATED SURVIVAL IN STAGE IIIB NON-SMALL CELL LUNG CANCER TREATED WITH CONCURRENT CHEMORADIOTHERAPY AT NATIONAL LUNG HOSPITAL. Vietnam Medical Journal, 548(1). https://doi.org/10.51298/vmj.v548i1.13363

EVALUATED SURVIVAL IN STAGE IIIB NON-SMALL CELL LUNG CANCER TREATED WITH CONCURRENT CHEMORADIOTHERAPY AT NATIONAL LUNG HOSPITAL

Hạnh Cấn Xuân, Lượng Đinh Văn

Main Article Content

Abstract

Objective: To evaluate progression-free survival (PFS) and overall survival (OS) in patients with stage IIIB non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy at the National Lung Hospital. Methods: A retrospective and prospective study was conducted on 66 patients with stage IIIB NSCLC who underwent concurrent chemoradiotherapy. Key variables included PFS, OS, and their associations with histopathology, age groups, and performance status (PS). Kaplan-Meier analysis was used for survival estimation, and log-rank tests were performed for subgroup comparisons. Results: Median PFS was 11.8 months, and median OS was 18.2 months. The 1-year and 2-year survival rates were 64.3% and 37.2%, respectively. Subgroup analysis showed no significant differences in PFS or OS across age groups, histological types, and PS scores (p > 0.05). Conclusion: Concurrent chemoradiotherapy offers promising survival outcomes for stage IIIB NSCLC patients, with consistent efficacy across different subgroups.

Article Details

Keywords

Stage IIIB non-small cell lung cancer, concurrent chemoradiotherapy, treatment efficacy, adverse events, National Lung Hospital

References

1. Freddie Bray., Mathieu Laversanne. , Hyuna Sung., et al (2024), Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA Cancer J Clin. 74(3), 229-263
2. Anh, L.T., Hóa xạ trị đồng thời ung thư phổi không tế bào nhỏ giai đoạn III. 2017, Trường Đại học Y dược thành phố Hồ Chí Minh.
3. Khiêm, V.H., Đánh giá kết quả điều trị ung thư phổi không tế bào nhỏ bằng phác đồ hoá - xạ trị với kỹ thuật PET/CT mô phỏng. 2017, Đại học Y Hà Nội.
4. Choy, H., et al., Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Journal of Clinical Oncology, 1998-Oct. 16(10).
5. Huber, R.M., et al., Simultaneous Chemoradiotherapy Compared With Radiotherapy Alone After Induction Chemotherapy in Inoperable Stage IIIA or IIIB Non–Small-Cell Lung Cancer: Study CTRT99/97 by the Bronchial Carcinoma Therapy Group. Journal of Clinical Oncology, 2006-September-20. 24(27).
6. Toàn, B.C. and N.V. Long, Đáp ứng điều trị và thời gian sống thêm của ung thư phổi không tế bào nhỏ giai đoạn III theo phác đồ hóa-xạ trị đồng thời. Nghiên cứu y học, 2012. 15: p. 162-168.
7. Aupérin, A., et al., Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010-5-1.